BioRestorative Therapies (BRTX) EBITDA Margin (2012 - 2025)
BioRestorative Therapies' (BRTX) quarterly EBITDA Margin came in at 19516.84% in Q4 2025, down 1330404.0% YoY from N/an in Q4 2024, and up 37.91% on a QoQ basis from 31432.3% in Q3 2025.
BioRestorative Therapies (BRTX) EBITDA Margin (2012 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 14 years of EBITDA Margin data on file, last reported at 19516.84% in Q4 2025.
- Quarterly EBITDA Margin fell 1330404.0% year-over-year to 19516.84% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 4350.05% (down 146846.0% YoY) and the FY2025 annual result came in at 4350.05%, down 146846.0% from the prior year.
- EBITDA Margin improved to 19516.84% in Q4 2025, from 31432.3% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 979.02% in Q3 2024 to a low of 126537.95% in Q4 2022.
- A 5-year average of 27861.49% and a median of 17575.52% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2021 — EBITDA Margin sank 8048702 bps — and 2023, when it soared 10985047 bps.
- Tracing BRTX's EBITDA Margin over 5 years: stood at 80185.34% in 2021, then sank by 58 bps to 126537.95% in 2022, then surged by 87 bps to 16687.47% in 2023, then surged by 63 bps to 6212.8% in 2024, then plunged by 214 bps to 19516.84% in 2025.
- The last three EBITDA Margin figures came in at 19516.84% (Q4 2025), 31432.3% (Q3 2025), and 1089.77% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | -19,516.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -19,516.84% |
| Sep 30, 2025 | -31,432.30% |
| Jun 30, 2025 | -1,089.77% |
| Mar 31, 2025 | -19,230.14% |
| Dec 31, 2024 | -6,212.80% |
| Sep 30, 2024 | -979.02% |
| Jun 30, 2024 | -2,770.83% |
| Mar 31, 2024 | -11,740.72% |
| Dec 31, 2023 | -16,687.47% |
| Sep 30, 2023 | -10,112.19% |
| Jun 30, 2023 | -4,831.86% |
| Mar 31, 2023 | -18,463.57% |
| Dec 31, 2022 | -126,537.95% |
| Sep 30, 2022 | -15,895.52% |
| Jun 30, 2022 | -6,510.03% |
| Mar 31, 2022 | -31,586.21% |
| Dec 31, 2021 | -80,185.34% |
| Sep 30, 2021 | -46,108.59% |
| Jun 30, 2021 | -23,701.75% |
| Mar 31, 2021 | -83,636.98% |